Company / Capital Expenditures
Nurix Therapeutics, Inc. Capital Expenditures History
FY2019-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Capital Expenditures
$14.0M
FY2025
5-year range
$1.7M / $14.0M
FY2021-FY2025
Trend
+51.0%
vs FY2024
Sector context
#49 of 194
Health Care
What the data says
Nurix Therapeutics, Inc.'s capital expenditures of $14M is higher than 75% of companies in the Health Care sector (FY2025). Capital Expenditures has increased for 4 consecutive years, from $2M in FY2021 to $14M in FY2025.
Based on SEC 10-K filings.
$14M in FY2025 with a 5-year CAGR of +25.2%. Top quartile in the Health Care sector.
Improved from $8M to $14M over the past 2 years.
Health Care sector context is included.
Capital Expenditures over time
Growth rates
- 3-Year CAGR
- +35.2%
- 5-Year CAGR
- +25.2%
- 10-Year CAGR
- -
Sector benchmark
-88.1% below sector average
Key checks
Key Insights
- Nurix Therapeutics, Inc.'s capital expenditures has grown for 4 consecutive years.
- 5-year CAGR of +25.2%, indicating consistent growth.
- In FY2025, capital expenditures increased 51.0% year-over-year.
- Ranks #49 out of 194 companies in the Health Care sector.
Company context
Key Data Points
- Altman Z-Score -0.35 (distress zone, below 1.8 threshold)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Capital ExpendituresValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $14.0M | +51.0% |
| FY2024 | $9.3M | +10.4% |
| FY2023 | $8.4M | +48.4% |
| FY2022 | $5.7M | +242.9% |
| FY2021 | $1.7M | -63.7% |
| FY2020 | $4.6M | +175.8% |
| FY2019 | $1.7M | - |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026